DRG Epidemiology's coverage of type 1 diabetes comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and diagnosed prevalence of type 1 diabetes for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

DRG Epidemiology's type 1 diabetes forecast will answer the following questions:

  • Of all people with type 1 diabetes, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of type 1 diabetes over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following type 1 diabetes patient populations:

  • Diagnosed prevalent cases.
  • Diagnosed prevalent cases by drug treatment.
  • Diagnosed incident cases.

Note: Coverage may vary by country and region.

Table of contents

  • Type 1 Diabetes - Epidemiology - Emerging Markets
    • Introduction
      • Key Findings
        • Key Updates
        • Overview
          • Diagnosed Prevalence of Type 1 Diabetes per 1,000 People of All Ages in 2020 and 2030
          • Relative Sizes of the Factors Contributing to the Trend in Diagnosed Prevalent Cases of Type 1 Diabetes over the Next 10 Years
          • Number of Additional Diagnosed Prevalent Cases of Type 1 Diabetes in 2030 in the Countries Under Study due to Trends in Risk or Survival
      • Epidemiology Data
      • Methods
        • Diagnosed Incident Cases of Type 1 Diabetes
        • Diagnosed Prevalent Cases of Type 1 Diabetes
        • Diagnosed Drug-Treated Prevalent Cases
        • Lifetime DALYs Gained
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Type 1 Diabetes
          • Studies Excluded from the Analysis of Type 1 Diabetes
        • Risk/Protective Factors
          • Risk/Protective Factors for Type 1 Diabetes
        • Bibliography
        • Glossary

    Author(s): Brynna Izquierdo; T.J. Arndt, MPH, CPH

    T.J. joined Decision Resources Group in 2018 as an entry-level epidemiologist and previously worked in basic sciences research academia.

    T.J. earned his Masters in Public Health from the University of Florida, where he conducted an internship focused on developing a clinical model to non-invasively screen for Non-Alcoholic Steatohepatitis (NASH). He also holds a B.S. in Microbiology & Cell Science and a B.A. in Spanish, both from the University of Florida. During his undergraduate and graduate career, he worked in two physiology-based research labs at the University of Florida, focusing on maternal and fetal stresses during pregnancy and parturition.

    Related Reports

    Type 1 Diabetes - Landscape & Forecast - Disease Landscape & Forecast

    The number of treatment options continues to increase in the T1D space. Existing agents fail to provide sustained and intrinsic control of

    View Details